10 September 2019 | News
Poster on ‘The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumor location’ to be presented during 22nd -24th November in Singapore
Photo credit: LinkedIn
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused Biopharma Company, on 10 Sep 2019 announced that an abstract on its lead candidate, varlitinib, has been accepted for poster presentation at the ESMO Asia Congress 2019 in Singapore on 22 November – 24 November.
Data comparing the therapeutic response between varlitinib plus capecitabine and lapatinib plus capecitabine by analyzing the changes of tumor volume per tumor location in patients with HER2-positive metastatic breast cancer after trastuzumab therapy will be presented.
The abstract (Abstract #681), titled ‘The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumor location’, will be available online at https://www.esmo.org/Conferences/ESMO-Asia-Congress-2019 on 19 November.